Business · Companies · 1 day ago
ME Therapeutics extends option for CD22 cancer therapy asset
ME Therapeutics, a biotechnology company, has extended an option agreement involving a cancer-treatment asset.
The asset is a nanobody-based binder that targets CD22, a molecule used in the company’s planned CAR therapy work.
It is owned by the National Research Council of Canada.
The agreement gives ME Therapeutics the option to license the binder, but does not say that the company has taken out a licence.
The company plans to keep developing it as part of its in vivo CAR program.
The option can now be exercised until February 10, 2027.
The other terms of the agreement remain unchanged.
ME Therapeutics extended its option agreement to license a Canadian government research agency’s CD22 nanobody for cancer therapy.
The option to license the asset is now exercisable until February 10, 2027.
The company said it will continue developing the nanobody as part of its in vivo CAR program.
All other terms of the agreement remain unchanged.
- Who
- ME Therapeutics Holdings Inc. and the National Research Council of Canada.
- What
- ME Therapeutics extended its option to license the NRC’s CD22 nanobody-based binder.
- When
- Announced October 9, 2026; the option is exercisable until February 10, 2027.
- Where
- Vancouver, British Columbia.
- Why
- The nanobody is intended for use in CAR therapy, and ME Therapeutics will continue developing it as part of its in vivo CAR program.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Company
- ME Therapeutics Holdings Inc.
- Asset
- NRC’s nanobody-based CD22 binder
- Extended option deadline
- February 10, 2027
- Development program
- In vivo CAR program
Sources
Related news
Court dismisses Tim Hortons class-action lawsuit
GM recalls more trucks over side-curtain airbag risk
Canada loses 68,000 jobs in September as unemployment rate rises to 6.5%
Shell to buy 30% stake in proposed Bay du Nord oil project
Kevin's Natural Foods turkey gravy recalled over undeclared mustard
Roblox resale earnings helped 25-year-old buy a Windsor home
Stelco says it will proceed with Ontario layoffs despite Ottawa's warning
Geely plans to start selling cars in Canada in 2027
Moms Offering More and Archewell launch crewneck supporting Alliance for Moms
Research links protected workloads to stronger workplace performance
Alberta farmers face trade and transport questions if province separates
